Novartis Leprosy Treatment Receives FDA Approval, Enhancing Patient Access

The FDA has approved Novartis' supplemental new drug application for Lamprene (clofazimine), a medication for leprosy. This decision eliminates previous managed access program restrictions, allowing patients to obtain the drug for free through a specialty pharmacy. The approval is expected to significantly improve access to this essential treatment for individuals with leprosy.